Stool DNA Methylation Markers for Early Neoplasm Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening methods for pancreatic and colorectal cancers are inefficient and impractical for the general population, with existing biomarkers having low sensitivity and specificity, especially when detected from stool samples, limiting early detection and treatment opportunities.
Innovation Solution
Development of methylated DNA markers and panels for pancreatic and colorectal cancers that provide high signal-to-noise ratios and low background levels, allowing for accurate detection from stool samples by analyzing the methylation state of specific chromosomal regions using advanced techniques such as methylation-specific PCR and next-generation sequencing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current screening methods are used for pancreatic and colorectal cancers, then the screening can be performed on the general population, but the sensitivity and specificity of detection are low
Solution Approach 1:
The patent changes the detection parameter from general biomarkers to methylated DNA markers with specific methylation patterns. By analyzing the methylation state of CpG islands in specific genes (such as BMP3, NDRG4, SFRP1, VIM, and CDX2), the method achieves higher sensitivity and specificity for detecting pancreatic and colorectal cancers in stool samples, resolving the contradiction between detection accuracy and screening efficiency.
2Ease of operation
If existing biomarkers are detected from stool samples, then non-invasive screening is achieved, but the signal-to-noise ratio is low and background levels are high
Solution Approach 1:
The patent extracts and isolates methylated DNA from stool samples using specific extraction methods that separate methylated DNA from unmethylated DNA and other background materials. This extraction process enriches the target methylated DNA markers, significantly improving the signal-to-noise ratio and detection precision while maintaining the convenience of non-invasive stool sample collection.
Solution Approach 2:
The patent uses methylated DNA as an intermediary marker that is shed by tumors into the gastrointestinal lumen and ultimately into stool. This intermediary allows indirect detection of pancreatic and colorectal cancers through easily collectable stool samples, bridging the gap between invasive tumor detection and non-invasive sampling while achieving high detection precision.
3Reliability
If aggressive screening strategies using computed tomography scans or endoscopic ultrasound are used, then detection yield for neoplasia increases to 10%, but the strategy is impractical for the general population
Solution Approach 1:
The patent employs a simple, inexpensive stool-based DNA detection method that can be easily performed in clinical laboratories. The method uses affordable PCR-based techniques to detect methylated DNA markers in stool samples, replacing complex and expensive imaging technologies like CT scans and endoscopic ultrasound. This makes high-yield screening practical for the general population through simple, disposable-like stool sample collection and analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The technology enables sensitive and specific detection of pancreatic and colorectal cancers, providing a high signal-to-noise ratio and low background levels, thereby improving early detection and treatment opportunities.
Implementation Method 1
Development of methylated DNA markers and panels for pancreatic and colorectal cancers that provide high signal-to-noise ratios and low background levels, allowing for accurate detection from stool samples by analyzing the methylation state of specific chromosomal regions
Implementation Method 2
analyzing the methylation state of specific chromosomal regions using advanced techniques such as methylation-specific PCR
Data Source
AI summary
Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.